Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.

Young K, Painter RE, Raghoobar SL, Hairston NN, Racine F, Wisniewski D, Balibar CJ, Villafania A, Zhang R, Sahm DF, Blizzard T, Murgolo N, Hammond ML, Motyl MR.

BMC Microbiol. 2019 Jul 4;19(1):150. doi: 10.1186/s12866-019-1522-7.

2.

Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.

Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF.

Diagn Microbiol Infect Dis. 2019 May 8. pii: S0732-8893(19)30352-9. doi: 10.1016/j.diagmicrobio.2019.05.001. [Epub ahead of print]

PMID:
31174995
3.

Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.

Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Gueny ME, Sahm DF.

J Antimicrob Chemother. 2019 Aug 1;74(8):2284-2288. doi: 10.1093/jac/dkz191.

PMID:
31086960
4.

Genomic characterization of IMP and VIM carbapenemase-encoding transferable plasmids of Enterobacteriaceae.

Matsumura Y, Peirano G, Bradford PA, Motyl MR, DeVinney R, Pitout JDD.

J Antimicrob Chemother. 2018 Nov 1;73(11):3034-3038. doi: 10.1093/jac/dky303.

PMID:
30099521
5.

Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.

Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF.

J Glob Antimicrob Resist. 2018 Dec;15:140-147. doi: 10.1016/j.jgar.2018.07.012. Epub 2018 Jul 30.

PMID:
30071354
6.

Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016.

Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF.

J Glob Antimicrob Resist. 2018 Dec;15:12-19. doi: 10.1016/j.jgar.2018.05.017. Epub 2018 May 29.

PMID:
29857057
7.

In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program.

Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00169-18. doi: 10.1128/AAC.00169-18. Print 2018 Jul.

8.

Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012-2016.

Lob SH, Hackel MA, Hoban DJ, Young K, Motyl MR, Sahm DF.

Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1481-1489. doi: 10.1007/s10096-018-3274-y. Epub 2018 May 12.

PMID:
29754209
9.

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.

Karlowsky JA, Lob SH, Kazmierczak KM, Hawser SP, Magnet S, Young K, Motyl MR, Sahm DF.

J Antimicrob Chemother. 2018 Jul 1;73(7):1872-1879. doi: 10.1093/jac/dky107.

PMID:
29659861
10.

Genomic epidemiology of global Klebsiella pneumoniae carbapenemase (KPC)-producing Escherichia coli.

Stoesser N, Sheppard AE, Peirano G, Anson LW, Pankhurst L, Sebra R, Phan HTT, Kasarskis A, Mathers AJ, Peto TEA, Bradford P, Motyl MR, Walker AS, Crook DW, Pitout JD.

Sci Rep. 2017 Jul 19;7(1):5917. doi: 10.1038/s41598-017-06256-2.

11.

Genomic epidemiology of global VIM-producing Enterobacteriaceae.

Matsumura Y, Peirano G, Devinney R, Bradford PA, Motyl MR, Adams MD, Chen L, Kreiswirth B, Pitout JDD.

J Antimicrob Chemother. 2017 Aug 1;72(8):2249-2258. doi: 10.1093/jac/dkx148.

12.

In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program).

Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02209-16. doi: 10.1128/AAC.02209-16. Print 2017 Jun.

13.

In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014.

Karlowsky JA, Lob SH, Kazmierczak KM, Badal RE, Young K, Motyl MR, Sahm DF.

J Clin Microbiol. 2017 Jun;55(6):1638-1649. doi: 10.1128/JCM.02316-16. Epub 2017 Mar 15.

14.

Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.

Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, Karlowsky JA, Sahm DF.

Diagn Microbiol Infect Dis. 2017 Jun;88(2):171-176. doi: 10.1016/j.diagmicrobio.2017.02.018. Epub 2017 Mar 2.

PMID:
28291628
15.

Global Molecular Epidemiology of IMP-Producing Enterobacteriaceae.

Matsumura Y, Peirano G, Motyl MR, Adams MD, Chen L, Kreiswirth B, DeVinney R, Pitout JD.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02729-16. doi: 10.1128/AAC.02729-16. Print 2017 Apr.

16.

Global Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 Gene.

Matsumura Y, Pitout JD, Gomi R, Matsuda T, Noguchi T, Yamamoto M, Peirano G, DeVinney R, Bradford PA, Motyl MR, Tanaka M, Nagao M, Takakura S, Ichiyama S.

Emerg Infect Dis. 2016 Nov;22(11):1900-1907. doi: 10.3201/eid2211.160519.

17.

Complete Sequencing of Plasmids Containing blaOXA-163 and blaOXA-48 in Escherichia coli Sequence Type 131.

Stoesser N, Sheppard AE, Peirano G, Sebra R, Lynch T, Anson L, Kasarskis A, Motyl MR, Crook DW, Pitout JD.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6948-6951. doi: 10.1128/AAC.01130-16. Print 2016 Nov.

18.

New Antimicrobial Agents  …  but No Susceptibility Tests!

Ambler JE, Krause KM, Steenbergen JN, Scangarella-Oman NE, Miller LA, Bhagwat SS, Serio AW, Chesnel L, Mahoney NM, Motyl MR, Critchley IA, Iaconis JP, Stone GG, Alder J, Xerri L, McCurdy SP, van Veenhuyzen DF, Grossman T, Echols RM, Williams G, Bradford PA.

Clin Infect Dis. 2016 Dec 1;63(11):1530-1531. Epub 2016 Aug 31. No abstract available.

PMID:
27581762
19.

First Report of blaIMP-14 on a Plasmid Harboring Multiple Drug Resistance Genes in Escherichia coli Sequence Type 131.

Stoesser N, Sheppard AE, Peirano G, Sebra RP, Lynch T, Anson LW, Kasarskis A, Motyl MR, Crook DW, Pitout JD.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):5068-71. doi: 10.1128/AAC.00840-16. Print 2016 Aug.

20.

Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model.

Mavridou E, Melchers RJ, van Mil AC, Mangin E, Motyl MR, Mouton JW.

Antimicrob Agents Chemother. 2015 Feb;59(2):790-5. doi: 10.1128/AAC.03706-14. Epub 2014 Nov 17.

21.

Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.

Jiménez-Ortigosa C, Paderu P, Motyl MR, Perlin DS.

Antimicrob Agents Chemother. 2014;58(2):1248-51. doi: 10.1128/AAC.02145-13. Epub 2013 Dec 9.

22.

In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods.

Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M.

Antimicrob Agents Chemother. 2013 Feb;57(2):1065-8. doi: 10.1128/AAC.01588-12. Epub 2012 Dec 10.

23.

Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST).

Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M.

J Antimicrob Chemother. 2013 Apr;68(4):858-63. doi: 10.1093/jac/dks466. Epub 2012 Nov 28.

PMID:
23190764
24.

In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.

Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH.

Antimicrob Agents Chemother. 2012 Jul;56(7):3753-7. doi: 10.1128/AAC.05927-11. Epub 2012 Apr 23.

25.

Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.

Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BD, Brown SD, Chaturvedi V, Fowler CL, Ghannoum MA, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Walsh TJ.

Diagn Microbiol Infect Dis. 2011 Jul;70(3):330-43. doi: 10.1016/j.diagmicrobio.2011.03.002. Epub 2011 May 4. Review.

PMID:
21546199
26.

Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.

Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Espinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Sheehan DJ, Walsh TJ; Clinical and Laboratory Standards Institute Antifungal Testing Subcommittee.

J Clin Microbiol. 2009 Oct;47(10):3142-6. doi: 10.1128/JCM.00940-09. Epub 2009 Aug 19.

27.

Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapy.

DiNubile MJ, Friedland IR, Chan CY, Motyl MR, Giezek H, McCarroll K, Shivaprakash M, Quinn JP, Weinstein RA, Chow JW.

Diagn Microbiol Infect Dis. 2007 Aug;58(4):491-4. Epub 2007 May 16.

PMID:
17509789
28.

Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.

DiNubile MJ, Chow JW, Satishchandran V, Polis A, Motyl MR, Abramson MA, Teppler H.

Antimicrob Agents Chemother. 2005 Aug;49(8):3217-21.

29.

Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy.

Dinubile MJ, Friedland I, Chan CY, Motyl MR, Giezek H, Shivaprakash M, Weinstein RA, Quinn JP.

Eur J Clin Microbiol Infect Dis. 2005 Jul;24(7):443-9.

PMID:
15990986
30.

The recovery of Mycobacterium avium complex and Mycobacterium tuberculosis from blood specimens of AIDS patients using the nonradiometric BACTEC NR 660 medium.

Motyl MR, Saltzman B, Levi MH, McKitrick JC, Friedland GH, Klein RS.

Am J Clin Pathol. 1990 Jul;94(1):84-6.

PMID:
2113765
31.

Rapid detection of positive blood cultures with the BACTEC NR-660 does not require first-day subculturing.

Levi MH, Gialanella P, Motyl MR, McKitrick JC.

J Clin Microbiol. 1988 Nov;26(11):2262-5.

32.

Mycobacterium tuberculosis bacteremia in the acquired immunodeficiency syndrome.

Saltzman BR, Motyl MR, Friedland GH, McKitrick JC, Klein RS.

JAMA. 1986 Jul 18;256(3):390-1. No abstract available.

PMID:
3088290
33.
34.
35.

Diagnosis of herpesvirus infections: correlation of Tzanck preparations with viral isolation.

Motyl MR, Bottone EJ, Janda JM.

Diagn Microbiol Infect Dis. 1984 Apr;2(2):157-60.

PMID:
6201317
36.

Plasmodium falciparum: comparison of in vitro growth of knobby and knobless isolates.

Motyl MR, Reese RT.

Am J Trop Med Hyg. 1983 Mar;32(2):226-30.

PMID:
6340540
37.

Reaction of immune sera with components of the human malarial parasite, Plasmodium falciparum.

Reese RT, Motyl MR, Hofer-Warbinek R.

Am J Trop Med Hyg. 1981 Nov;30(6):1168-78.

PMID:
7034560
38.

Plasmodium falciparum: loss of knobs on the infected erythrocyte surface after long-term cultivation.

Langreth SG, Reese RT, Motyl MR, Trager W.

Exp Parasitol. 1979 Oct;48(2):213-9. No abstract available.

PMID:
383488

Supplemental Content

Loading ...
Support Center